Document 260989

STRUCTURED SALES MATERIAL
100% Capital Protected Deposit – Global Pharmaceuticals 1
December 2012
For Professional Investors Only
Investment linked to a basket of US, European and Japanese Pharmaceutical stocks, providing the
opportunity for annual returns of up to 5.00% over the first 4 years and exposure to the performance of the
underlying stocks at the end of year 5. The investment is 100% capital protected at the Account Closing Date
Product Summary
Key Features
Product
Global Pharmaceuticals 1 - Deposit
Deposit Taker
Nomura Bank International plc („NBI‟), rated as
A- by S&P

The Nomura Global Brands 1 (“the Deposit”) is
linked to a basket of US, European and Japanese
Pharmaceutical stocks

The Deposit provides investors with the potential for
returns of 5.00% for each of the first 4 years,
combined with participation in the performance of the
underlying stocks at the Final Valuation Date.

The Deposit taker is Nomura Bank International plc
(“the Issuer”), which is rated by S&P as A-, at the
time of a publication

The Deposit is available in USD, GBP and has an
investment term of 5 years, and is intended to be
held for the entire period

The 100% Capital Protection only applies at
Maturity
Investment Term 5 years
Currency
Available in USD and GBP
Underlying
Assets
GlaxoSmithKline Plc (GSK LN Equity)
Johnson & Johnson (JNJ US Equity)
Novartis AG (NOVN VX Equity)
Abbott Laboratories (ABT US Equity)
Takeda Pharmaceutical Co Ltd (4502 JT Equity)
Key Dates
Initial Valuation Date: 15 January 2013
Deposit Date: 22 January 2013
Final Valuation Date: 15 January 2018
Account Closing Date (Maturity): 22 January
2018
Investment Description

Conditional
5.00%
Coupon Amount
A 5 year investment linked to the performance of the
stocks of GlaxoSmithKline Plc, Johnson &
Johnson, Novartis AG, Abbott Laboratories and
Takeda Pharmaceutical Co Ltd
Conditional
Coupon
Following each Conditional Coupon Observation
Date, if the price of each underlying is greater
than or equal to 105% of its Initial Valuation
Level the Deposit will pay a coupon of 5.00%

Redemption
Value
100% + Performance of the Worst Performing
Asset
(subject to minimum value of 100%)
Your initial investment is made at a price of 100%,
and there is potential on each of the 4 annual
Conditional Coupon Observation Dates to receive a
5% coupon

Capital Risk
100% Capital Protected at the Account Closing
Date.
The Value of the deposit may be more or less
than 100% prior to the Account Closing Date
In addition to the potential for income, at the end of
year 5, the investor will participate in the
performance of the Worst Performing Asset. For
example if GlaxoSmithKline Plc has returned +20%
over the 5 year period and is the worst performing
asset, the investor will receive 120% of their
invested capital

In the worst case scenario at maturity, if all of the
Underlying Assets have performed negatively. The
investor will still have 100% of capital invested
returned at the 5 year maturity
Initial Valuation The level or price of each Underlying at the close
Level
of the Initial Valuation Date
Final Valuation
Level
The level or price of each Underlying at the close
of the Final Valuation Date
Conditional
Coupon
Observation
Dates
15 January
15 January
15 January
16 January
Worst
Performing
Asset
The Underlying Asset with the lowest
Performance at the scheduled closing time on
each Conditional Coupon Observation Date and
the Final Valuation Date
Performance
(Final Valuation Level / Initial Valuation Level) - 1
Product
Reference
Global Pharmaceuticals 1 USD Deposit
Global Pharmaceuticals 1 GBP Deposit
2014,
2015,
2016,
2017
Investor Returns at Account Closing Date
Performance of Worst
Performing Underlying at
Maturity (Final / Initial Level)
140%
120%
100%
80%
60%
40%
20%
0%
Redemption Amount at
Maturity
140%
120%
100%
100%
100%
100%
100%
100%
100% Capital Protected Deposit – Global Pharmaceuticals 1
December 2012
The Underlying Assets
GlaxoSmithKline Plc

GlaxoSmithKline
PLC
is
a
research-based
pharmaceutical company. The Company develops,
manufactures, and markets vaccines, prescription, and
over-the-counter medicines, as well as health-related
consumer products. GlaxoSmithKline provides products
for infections, depression, skin conditions, asthma,
heart & circulatory disease, and cancer.
5 Year Performance
140
120
100
80
60
40
20
0
Dec-07
Dec-08
Johnson & Johnson

The Johnson & Johnson manufactures health care
products and provides related services for the
consumer, pharmaceutical, and medical devices and
diagnostics markets. The Company sells products
such as skin and hair care products, acetaminophen
products, pharmaceuticals, diagnostic equipment, and
surgical equipment in countries located around the
world.
Dec-11
Dec-12
Dec-11
Dec-12
Dec-11
Dec-12
Dec-11
Dec-12
Dec-11
Dec-12
100
80
60
40
20
0
Dec-07
Dec-08
Dec-09
Dec-10
5 Year Performance
Novartis AG manufactures pharmaceutical and
consumer healthcare products. The Company
produces
pharmaceuticals
for
cardiovascular,
respiratory and infectious diseases; oncology,
neuroscience,
transplantation,
dermatology,
gastrointestinal and urinary conditions, and arthritis;
vaccines and diagnostics; vision, and animal health
products.
120
100
80
60
40
20
0
Dec-07
Dec-08
Abbott Laboratories

Dec-10
120
Novartis AG

Dec-09
5 Year Performance
Abbott Laboratories discovers, develops, manufactures,
and sells a broad and diversified line of health care
products and services. The Company's products
include pharmaceuticals, nutritional, diagnostics, and
vascular products. Abbott markets its products
worldwide through affiliates and distributors.
Dec-09
Dec-10
5 Year Performance
140
120
100
80
60
40
20
0
Dec-07
Dec-08
Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited mainly
manufactures
and
sells
pharmaceuticals,
food
supplements, and chemical products like polyurethane.
The Company also produces food, agrochemicals, and
environment-related products such as pollution
detectors.
Takeda Pharmaceutical researches,
develops, and promotes the products through its related
companies in the US, Europe, and Asia.
Dec-09
Dec-10
5 Year Performance
120
100
80
60
40
20
0
Dec-07
Dec-08
Dec-09
Dec-10
Source for company descriptions and historical prices, Bloomberg, as of 11 December 2012. Charts are indexed at 100 starting on 11 December 2007
Past performance is no indication of future performance
This publication has been issued by the Sales/Trading departments of Nomura International plc, in order to promote investment services and is provided without
compensation. This document should not be considered an offer to buy or sell investments. We are not your designated investment adviser and this information
is therefore provided on the basis that you have such knowledge and experience to evaluate its merits and risks, and are capable of undertaking your own
objective analysis of the investment and its suitability to meet your requirements. The information is based on sources we believe to be reliable, but we do not
represent that it is accurate or complete. Any valuations contained herein are subject to change without notice. Nomura International plc and/or connected
persons do not accept any liability whatsoever for any direct, incorrect or inconsequential loss arising from any use of the information or its content. Nomura
International plc is authorised and regulated by the Financial Services Authority.
100% Capital Protected Deposit – Global Pharmaceuticals 1
Annual Observation Dates and the Final Valuation Date
Month 12:
Are all Underlying Assets at, or above 105% of their
initial level?
Deposit Returns
5.00% Coupon
Yes
No
Month 24:
Are all Underlying Assets at, or above 105% of their
initial level?
5.00% Coupon
Yes
No
Full Product Term
is 5 years
At Maturity,
Month 60:
This check is performed every 12 months for first 4 years
Are all Underlying Assets at, or above 100% of their
initial level?
Yes
Deposit redeems at: 100% capital +
Performance of Worst Performing Asset
No
Deposit redeems at 100% of initial investment. i.e. the deposit is 100% Capital Protected at Maturity
Nomura – Global Reach

Nomura Bank International plc is part of the Nomura Group.
The ultimate parent company is Nomura Holdings, Inc.
(“Nomura”)

Nomura is a leading global investment bank:

Full range of products supported by a global network of more
than 35,000 employees in over 30 countries;

Nomura maintains a robust financial position and a healthy
balance sheet. As at the end of June 2012, Nomura‟s Tier 1
ratio was 15.0%, and shareholders‟ equity of 2.1 trillion yen.

Listed on Tokyo, New York, and Singapore stock exchanges.

Stable and well diversified revenues across regions

The Deposit is issued by Nomura Bank International plc,
and are NOT guaranteed by Nomura Holdings, Inc. or any
other group company.
Overview: Q1 2012/13 Net Revenue by Division
Wholesale
Banking
JPY 121.9bn
Retail
JPY 82.7bn
Asset Mgmt
JPY 16.4bn
Source: News Release: Nomura Reports First Quarter Financial Results, Nomura website: www.nomura.com as of July 2012.
Structured Sales Contacts




Tel:
Fax:
Email:
Web:
+44 (0) 207 103 5773
+44 (0) 207 521 1561
[email protected]
www.nomura.com

Nomura International plc
One Angel Lane
London
EC4R 3AB
This publication has been issued by the Sales/Trading departments of Nomura International plc, in order to promote investment services and is provided without
compensation. This document should not be considered an offer to buy or sell investments. We are not your designated investment adviser and this information
is therefore provided on the basis that you have such knowledge and experience to evaluate its merits and risks, and are capable of undertaking your own
objective analysis of the investment and its suitability to meet your requirements. The information is based on sources we believe to be reliable, but we do not
represent that it is accurate or complete. Any valuations contained herein are subject to change without notice. Nomura International plc and/or connected
persons do not accept any liability whatsoever for any direct, incorrect or inconsequential loss arising from any use of the information or its content. Nomura
International plc is authorised and regulated by the Financial Services Authority.
100% Capital Protected Deposit – Global Pharmaceuticals 1
December 2012
Disclaimer :
This information has been issued by the Sales/Trading departments of Nomura International plc ("NIplc") and is made available to you by
NIplc and/or its affiliates (collectively, "Nomura"), in order to promote investment services and is provided without compensation. This is
not investment research as defined by the UK Financial Services Authority ("FSA"), nor is it research under the rules of the U.S. Self
Regulatory Organizations of which Nomura is a member or under applicable rules in Hong Kong. Information contained herein is provided
for informational purposes only, is intended solely for your use and may not be quoted, circulated or otherwise referred to without our
express consent. This material contains indicative terms only, and should not be considered as an offer to buy or sell securities or other
products discussed herein. Any prices, yields and opinions expressed are subject to change without notice. The information is based on
sources we believe to be reliable, but we do not represent that it is accurate or complete. We are not your designated investment adviser
and this information is therefore provided on the basis that you have such knowledge and experience to evaluate its merits and risks, and
are capable of undertaking your own objective analysis of the investment and its suitability to meet your requirements. It does not
constitute a personal recommendation as defined by the FSA, or take into account the particular investment objectives, financial situations
or needs of individual investors. Nomura and/or connected persons do not accept any liability whatsoever for any direct, indirect or
consequential loss arising from any use of the information or its content. Nomura also may have acted as an underwriter of such
securities or other products discussed in this material, and may currently be providing investment banking services to the issuers of such
securities or products. Nomura and/or its officers, directors and employees, including persons, without limitation, involved in the
preparation or issuance of this material may, from time to time, have long or short positions in, and buy or sell, the securities, or
derivatives (including options) thereof, of companies mentioned herein, or related securities or derivatives. This material has been
approved for distribution in the United Kingdom and European Union by NIplc, which is authorised and regulated by the Financial
Services Authority and is a member of the London Stock Exchange. It is not intended for retail clients. It is intended only for investors who
are "eligible market counterparties" or "professional clients " as defined by the FSA, and may not, therefore, be redistributed to other
classes of investors. Any securities described herein may not have been registered under the U.S. Securities Act of 1933, and, in such
case, may not be offered or sold to U.S. investors unless they have been registered or sold in an exempted transaction. Nomura is the
global marketing name of Nomura Holdings, Inc. (Tokyo) and its direct and indirect subsidiaries worldwide including Nomura International
(Hong Kong) Limited, licensed and regulated by the Hong Kong Securities and Futures Commission, Nomura Securities International, Inc
(New York), a member of FINRA, NYSE and SIPC and Nomura International plc (London), authorised and regulated by the Financial
Services Authority (“FSA”) and member of the London Stock Exchange.
Nomura manages conflicts identified through the following: their Chinese Wall, confidentiality and independence policies, maintenance of
a Stop List and a Watch List, personal account dealing rules, policies and procedures for managing conflicts of interest arising from the
allocation and pricing of securities and impartial investment research and disclosure to clients via client documentation. Disclosure
information is available at http://www.nomura.com/research/.
This factsheet is for information only and use by professional financial advisors only, and should not be considered a financial
promotion. This information alone should not be relied on for making investment or purchasing decisions.
Who Can Invest in the Deposit?
The Deposit is available for purchase within the UK and offshore for the following three investor categories:
 Qualified Professional Investors
 Offshore Life Companies buying as principal
 Corporate and Institutional clients buying as principal
 Minimum Initial Investment per counterparty is GBP 50,000 or USD 50,000
Key Dates
Initial Strike Date
15 January 2013
Deposit Date
22 January 2013
Final Valuation Date
15 January 2018
Account Closing Date
22 January 2018
Risks

Please bear in mind that investors are exposed to the credit risk of the Deposit taker. Any secondary market
provided by Nomura International plc is subject to change and may be stopped without notice and investors
may therefore be unable to sell or redeem the Deposit until their maturity. If the Deposit is redeemed early
they may be redeemed at a level less than the amount originally invested.
Structured Sales Contacts




Tel:
Fax:
Email:
Web:
+44 (0) 207 103 5773
+44 (0) 207 521 1561
[email protected]
www.nomura.com

Nomura International plc
One Angel Lane
London
EC4R 3AB